Certain patient groups may be underrepresented or excluded from RCTs due to eligibility criteria, logistical barriers, ethical concerns or other reasons.
Examples of these potential groups are females, pregnant or breastfeeding females, older adults due to age or comorbidities, children, people with rare or orphan diseases, people from underserved or minority communities, non-binary or transgender individuals, people with mental health disorders, and people on polypharmacy.
RWE studies provide opportunities to derive evidence for patients who are excluded from clinical trials and to validate the generalisability of clinical findings.
RWE is increasingly informing regulatory bodies and shaping treatment guidelines.
Quantify Research specialises in designing RWE studies which includes studies focused on:
📊 Study underrepresented groups: Examine the safety and efficacy of treatments in populations often excluded from RCTs, including women.
🔍 Capture real-world complexities: Understand how comorbidities, age, and sex differences influence treatment outcomes.
📋Further evaluate the safety and effectiveness: Conduct post-authorisation safety studies (PASS) to ensure long-term safety.
⚖ Improve healthcare equity: Provide insights that help regulatory decisions and clinical guidelines to better serve all patients.
💡 Identify unmet need: Provide evidence on where existing treatments are insufficient, have significant side-effects, or where no approved treatments are available.
Contact us to collaborate in improving patient lives by generating evidence with everyone in mind.
